Oncolytic Viruses Mediating Anti-tumor Immunity in Human Cancer Patients Published by Oncos Therapeutics and University of Helsinki
May 19, 2010. Helsinki, Finland -- Oncos Therapeutics, a biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published today initial results from its Advanced Therapy Access Program in Cancer Research. The results demonstrate anti-tumor immunity of oncolytic viruses – published for the first time in humans – and indicate strong efficacy of the next generation viruses against solid tumor cancers. As of today, 200 patients have been treated with oncolytic virus therapy in the company’s Advanced Therapy Access Program.